In this post-authorization safety study in the Nordic countries, desloratadine (DL) exposed periods were associated with an elevated incidence rate of seizure compared to subsequent unexposed periods, with the largest effect for the exposed period following the first-ever DL prescription redemption.

In children aged 0–5 years, a marked increase in the incidence rate of febrile seizure was seen during DL exposed periods compared to unexposed periods.

Among adults, no difference in incidence rate of seizure was seen between DL exposed and unexposed periods.